News Author: Jen Smith Publish date: June 18, 2016
COPENHAGEN—The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have progressive or...
News Author: Jen Smith Publish date: June 16, 2016
COPENHAGEN—The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic synd...
News Author: Jen Smith Publish date: June 16, 2016
COPENHAGEN—Interim results from the phase 3 TOWER trial suggest blinatumomab can prolong overall survival (OS) when compared to standard care in ad...
News Author: Jen Smith Publish date: June 15, 2016
COPENHAGEN—The combination of daratumumab, lenalidomide, and dexamethasone (DRd) could become a new standard of care for patients with relapsed or ref...
News Author: Jen Smith Publish date: February 12, 2016
Photo by Larry Young
SAN FRANCISCO—A combination treatment regimen can produce durable remissions in patients newly diagnosed with peripheral T-cel...
News Author: Jen Smith Publish date: February 10, 2016
Photo by Larry Young
SAN FRANCISCO—A 3-agent chemotherapy regimen can be “highly effective” in patients with extranodal natural killer/T-cell lymph...
News Author: Jen Smith Publish date: February 9, 2016
Photo by Larry Young
SAN FRANCISCO—Preclinical research suggests a compound that inhibits both EZH1 and EZH2 could be effective against adult T-cel...
News Author: Jen Smith Publish date: February 5, 2016
Photo by Larry Young
SAN FRANCISCO—The PD-1-blocking antibody pembrolizumab can produce “significant objective clinical responses” in patients with...
News Author: Jen Smith Publish date: February 4, 2016
Photo by Larry Young
SAN FRANCISCO—Preclinical research has revealed mutations that may affect the performance of histone deacetylase inhibitors (H...
News Author: Jen Smith Publish date: February 3, 2016
Photo by Larry Young
SAN FRANCISCO—Results of a phase 2 trial suggest lenalidomide may be a treatment option for patients with relapsed adult T-cel...
News Author: Jen Smith Publish date: February 2, 2016
Photo by Larry Young
SAN FRANCISCO—The oral histone deacetylase inhibitor chidamide can elicit responses in patients with relapsed or refractory cu...
News Author: Jen Smith Publish date: January 3, 2016
Photo courtesy of ASH
ORLANDO, FL—Adding the oral proteasome inhibitor ixazomib to treatment with lenalidomide and dexamethasone can prolong progre...
News Author: Jen Smith Publish date: January 2, 2016
Photo courtesy of ASH
ORLANDO, FL—A subgroup of young patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL) can have “outstanding out...
News Author: Jen Smith Publish date: December 31, 2015
ORLANDO, FL—Having a higher grade of bone marrow (BM) fibrosis may confer inferior overall survival (OS) in patients with primary myelofibrosis (PMF),...
News Author: Jen Smith Publish date: December 31, 2015
ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with ad...
